Products - Allergies | Topic

Showing 12 products

Date | Sort by Title

Guidance programme: Technology appraisal guidanceRemove ‘Guidance programme: Technology appraisal guidance’ filter

Palforzia for treating peanut allergy in children and young people (TA769)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
2 February 2022
Berotralstat for preventing recurrent attacks of hereditary angioedema (TA738)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
20 October 2021
Lanadelumab for preventing recurrent attacks of hereditary angioedema (TA606)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
16 October 2019
Omalizumab for treating severe persistent allergic asthma (TA278)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
24 April 2013
Pharmalgen for the treatment of bee and wasp venom allergy (TA246)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 February 2012
STG320 for treating allergic rhinitis or rhinoconjunctivitis caused by house dust mites (ID1278)
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
26 June 2024
Mepolizumab for treating eosinophilic granulomatosis with polyangiitis ID1186
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Epicutaneous immunotherapy for treating peanut allergy in children [ID1255]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
SQ HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (ID3961)
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Benralizumab for treating eosinophilic oesophagitis in people aged 12 to 65 [ID 5093]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Dupilumab for treating eosinophilic oesophagitis in people 12 years and over [ID 5107]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Palforzia for treating peanut allergy in children aged 1 to 3 TS ID 10510
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC

Allergies Products

Filter

Product type

Guidance programme
1 selected

Status

New and updated

Showing 12 products

Palforzia for treating peanut allergy in children and young people (TA769)

Berotralstat for preventing recurrent attacks of hereditary angioedema (TA738)

Lanadelumab for preventing recurrent attacks of hereditary angioedema (TA606)

Omalizumab for treating severe persistent allergic asthma (TA278)

Pharmalgen for the treatment of bee and wasp venom allergy (TA246)

STG320 for treating allergic rhinitis or rhinoconjunctivitis caused by house dust mites (ID1278)

Mepolizumab for treating eosinophilic granulomatosis with polyangiitis ID1186

Epicutaneous immunotherapy for treating peanut allergy in children [ID1255]

SQ HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (ID3961)

Benralizumab for treating eosinophilic oesophagitis in people aged 12 to 65 [ID 5093]

Dupilumab for treating eosinophilic oesophagitis in people 12 years and over [ID 5107]

Palforzia for treating peanut allergy in children aged 1 to 3 TS ID 10510

Allergies Products

Filter

Product type

Guidance programme1 selected

Status

New and updated

Showing 12 products

Guidance programme
1 selected